News
September 12, 2023
Medcura Names Dr. John Barry and J.P. McAfee to Leadership Positions
July 18, 2023
Medcura Inc. Appoints Jacob Rodman to Board of Directors, Preparing for LifeGel™ Flowable Hemostat Launch and Expanding Market Reach
June 1, 2023
Distinguished Cardiac Surgeon Dr. Abbas Ardehali Joins Medcura's Board of Directors
May 24, 2023
Accomplished Scientist and Biosurgery Industry Veteran Dr. Neil Winterbottom Joins Medcura's Leadership Team
April 3, 2022
Medcura selected to participate in Silicon Valley 2023 Startup Grind Accelerate
February 21, 2023
Renowned Hemostat Innovator Joins Medcura to Drive Clinical Studies, Regulatory Pursuits
Rachel Hoffman Joins Medcura as SVP
January 12, 2022
Medcura Receives Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat®
LifeGel™ is the first and only hemostatic agent to receive Breakthrough Device Designation seeking a new and highly differentiated indication
December 10, 2022
Medcura Launches a New Class of High-Performance, Antibacterial Hemostats online and through a leading drugstore in the U.S. market
Walmart.com joins the ranks of massive retail operations, including Amazon and CVS, to offer Rapid-Seal®
October 11, 2022
Medcura Names New Surgical Scientific Advisory Board
Accomplished surgeons will provide expert guidance on Medcura's clinical, technical and market development.
September 15, 2022
New Medcura SVP Positions LifeGel™ Surgical Hemostat for Market Leadership
Steve Ford brings extensive experience in hemostatic agents to the company now disrupting that market with its highly effective, cost-saving, innovative platform
September 8, 2022
TEDCO Invests First of Maryland’s SSCBCI Funds in Medcura, Inc.
Maryland medical device company with advanced surgical non-thrombin hemostat platform receives $1M SSBCI funding from TEDCO
September 1, 2022
Injectable Non-Thrombin Foam Increases Survival Rates for Severe Internal Bleeding in Recent Research Study
Medcura’s LifeFoam™ product demonstrates significant life-saving potential
in massive noncompressible intra-abdominal hemorrhaging scenarios
June 6, 2022
Medcura Appoints Surgical Medical Device Leader Jim Buck as New CEO
Experienced technology-driven innovator aims to position and accelerate the company’s first-of-its-kind surgical technology platform
April 26, 2022
Medcura Expands its Senior Leadership Team and Appoints Leading Neurosurgeon Dr. Kenneth Renkens as Chief Medical Officer
Respected surgeon, innovator and builder of clinical businesses tapped to accelerate the development of first-of-its-kind surgical hemostat platform
August 12, 2021
Medcura raises $7.4 Million to Expand FDA-Approved Line of Hemostatic and Wound Treatment Products
Funds will allow Medcura to expand its commercial footprint and support IDE submission for a new class of surgical hemostat
July 12, 2021
Medcura Launches a New Class of High-Performance, Antibacterial Hemostats online and through a leading drugstore in the U.S. market
April 7, 2021
Medcura publishes successful results from clinical study Demonstrating rapid hemorrhage control and improved patient outcomes
February 23, 2021
Medcura expands Internal Hemostat Program with a follow-on grant from the U.S. Military
June 29, 2020
Medcura expands Management Team with experienced Business and Product Development leads
April 17, 2020
Medcura, Inc., a commercial-stage medical device company, announced today that it has moved into a new purpose-built facility in Riverdale, Maryland that will support the manufacture and commercialization of its growing product line.
December 19, 2019
gel-e, Inc. changes its name to Medcura … a name befitting the company poised to disrupt consumer, clinical and military markets
October 31, 2019
Continued Expansion of Medcura’s Consumer Products Label
June 18, 2019
Medcura Inc., announces Breakthrough Status Designation from the U.S. Food and Drug Administration (FDA) for its first internal-use flowable device
April 3, 2019
Medcura announces publication of recent study results in the Journal of Surgical Research
January 21, 2019
Medcura Expands Patent Estate
November 27, 2018
Medcura will be presenting at the MedTechStrategist Innovation Summit
Medcura will be presenting at the MedTechStrategist Innovation Summit at The Hyatt Regency in Burlingame, CA along with several other life sciences companies from around the US. To register and attend the event, go
here.
June 29, 2018
Medcura expands its OTC label
April 27, 2018
Medcura recognized by MedTech Daily
February 19, 2018
Medcura, Inc. Receives Grant to Develop New Internal Use Hemostats
January 9, 2018
Medcura, Inc., adds Dr. Grant Bochicchio to its Clinical Advisory Board
January 2, 2018
Medcura Presenting at the 10th Annual Biotech Showcase™ 2018 Conference
December 22, 2017
Medcura Expands Board of Directors with Domain & Commercial Strategy Expert
December 15, 2017
Medcura receives US FDA clearance to expand its bandage product line for Rx and OTC use
November 15, 2017
MTECH 30th Anniversary Maryland Industrial Partnerships (MIPS) Ceremony
Medcura will be presentating at the Q3 Ernerging Medical Technologies (EMT) Spotlight event on Friday Oct 20, 2017
September 17, 2017
Medcura Expands Core Team with Regulatory, Manufacturing and Financial Talent
July 13, 2017
Medcura Secures $3.1 Million Financing
February 1, 2017
New Notice of Trademark Allowance
The USPTO issued a notice of trademark allowance on the name
“gel-e,” which is at the core of our branding. This allowance continues the build of our intellectual property estate, and we believe it to be an important asset moving forward.
See Trademark Serial Number: 87/045,953
January 15, 2017
Biz Dev deal signed with the Jai Group
The Jai Group (JG) is a West Coast business development firm with a focus on pharmaceutical and medical device partnerships in Latin America. Medcura and JG just inked a deal through which JG will identify the best Latin American partners for Medcura’s currently cleared Vascular Access product as well as future products. JG has an excellent track record of obtaining valuable licensing and distribution partnerships in Latin America for their clients.
September 15, 2016
New Supplemental Grant from the National Science Foundation
Medcura is the recipient of a supplemental grant to our current SBIR Phase II Award from the National Science Foundation for $100,000. The award, called Small-Business / ERC (Engineering Reserach Center) Collaborative Opportunity (SECO), will go towards evaluating the safety of our chitosan-based foam in internal surgical applications. The Company will collaborate with Dr. Steven Stice who works at the Regenerative Engineering and Medicine Research Center, University of Georgia, where the studies will be conducted. This is an exciting development for our internal surgical research program.
